Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 7/20 | 1.00 |
| ▸ | OSBP | P22059 | 6/20 | 1.00 |
| ▸ | RORC | P51449 | 5/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.84 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.84 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.84 |
| ▸ | USP2 | O75604 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.84 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.84 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.80 |
| ▸ | CRYAB | P02511 | 1/20 | 0.76 |
| ▸ | HMGCR | P04035 | 1/20 | 0.76 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.76 |
| ▸ | ITGAV | P06756 | 1/20 | 0.76 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.76 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.76 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.72 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042866 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL6391967 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL288494 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL159618 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL23960515 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL13076858 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL24937893 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL1176969 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL22095720 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL22559557 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075388-A | Ophthalmic compositions for treating vision disorders | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026090423-A1 | UNIVERSAL LNP COMPOSITIONS | PRIME MEDICINE, INC (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| US-20250369986-A1 | APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS | The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University (CN) | 2025-12-04 | — | — | US | claimed |
| EP-4657069-A1 | APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS | The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University (CN) | 2025-12-03 | — | — | EP | claimed |
| US-20250345358-A1 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | MANDOS LLC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250345284-A1 | LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-11-13 | — | — | US | claimed |
| US-20250326839-A1 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250282866-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-09-11 | — | — | US | claimed |
| EP-3911302-B1 | DRUG DELIVERY SYSTEMS CONTAINING OXIDIZED CHOLESTEROLS | GEORGIA TECH RES INST (US) | 2025-09-10 | — | — | EP | claimed |
| WO-1996011008-A1 | ADMINISTRATION OF A 27-HYDROXYCHOLESTEROL OR PRODRUG THEREOF AS AN ANTI-CANCER AGENT | NEW YORK UNIVERSITY (US) | 1996-04-18 | — | — | WO | claimed |
| WO-1995015165-A1 | ADMINISTRATION OF A 27-HYDROXYCHOLESTEROL OR RELATED COMPOUND OR STEROL-27-HYDROXYLASE STIMULANT TO PREVENT RESTENOSIS FOLLOWING VASCULAR ENDOTHELIAL INJURI | NEW YORK UNIVERSITY MEDICAL CENTER (US) | 1995-06-08 | — | — | WO | claimed |
| US-5376652-A | Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury | NEW YORK UNIVERSITY MEDICAL CENTER (US) | 1994-12-27 | — | — | US | claimed |
| CN-1084856-A | The method for making of amino cholesterol | UNIV NEW YORK (US) | 1994-04-06 | — | — | CN | claimed |
| WO-1991015213-A1 | SIDE-CHAIN HYDROXYLATED CHOLESTEROL DERIVATIVES, AGENTS FOR DISSOLUTION OF CHOLESTEROL GALLSTONES | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1991-10-17 | — | — | WO | claimed |
| EP-0258434-A4 | COMPOSITION COMPRISING AN OXYGENATED CHOLESTEROL. | JAVITT NORMAN B (US) | 1989-11-07 | — | — | EP | claimed |
| US-4743597-A | ANTIINFLAMMATORY, PSORIASIS | WHITBY RESEARCH, INC. | 1988-05-10 | — | — | US | claimed |
| EP-0258434-A1 | COMPOSITION COMPRISING AN OXYGENATED CHOLESTEROL | JAVITT, Norman B. (US) | 1988-03-09 | — | — | EP | claimed |
| WO-1987004346-A1 | COMPOSITION COMPRISING AN OXYGENATED CHOLESTEROL AND USE THEREOF FOR TOPICAL TREATMENT OF DISEASES | JAVITT NORMAN B | 1987-07-30 | — | — | WO | claimed |
| US-4427668-A | 26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue | NEW YORK UNIVERSITY (US) | 1984-01-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345284-A1 | LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF | CD47, CETP, HAVCR2 | NR1H3 98/4885OSBP 421/4885RORC 22/4885 |
| US-20250345358-A1 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | GBA1, NPC1, GBA2 | NR1H3 71/4885OSBP 534/4885RORC 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.